Merlin, the product of NF2 gene, is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 172, Issue , 2017, Pages 222-230

  Cocciadiferro, Letizia ^a   Miceli, Vitale ^b   Granata, Orazia M ^c   Carruba, Giuseppe ^a  

^a Head of Research and Internationalization Unit (SIRS)   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^c G Di Cristina Children Hospital   (Italy)

Author keywords

Amphiregulin; Aromatase; Estrogen receptors; Hepatocellular carcinoma; Merlin

Indexed keywords

AROMATASE; ESTROGEN; MERLIN; AMPHIREGULIN; AREG PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; ISOPROTEIN;

ADULT; AGED; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TISSUE; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ALTERNATIVE RNA SPLICING; CANCER STEM CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; NEUROFIBROMATOSIS TYPE 2; PATHOLOGY; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; AMPHIREGULIN; AROMATASE; CARCINOMA, HEPATOCELLULAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; NEUROFIBROMATOSIS 2; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84979608904     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.05.023     Document Type: Review

References (33)

1. Trofatter, J.A., MacCollin, M.M., Rutter, J.L., Murrell, J.R., Duyao, M.P., Parry, D.M., Eldridge, R., Kley, N., Menon, A.G., Pulaski, K., A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell, 75(4), 1993, 826 (nov.).
2. McClatchey, A.I., Fehon, R.G., Merlin and the ERM proteins ?regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 19:5 (2009), 198–206 (mag.).
3. Asthagiri, A.R., Parry, D.M., Butman, J.A., Kim, H.J., Tsilou, E.T., Zhuang, Z., Lonser, R.R., Neurofibromatosis type 2. Lancet Lond. Engl. 373:9679 (2009), 1974–1986 (giu.).
4. Kissil, J.L., Wilker, E.W., Johnson, K.C., Eckman, M.S., Yaffe, M.B., Jacks, T., Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol. Cell 12:4 (2003), 841–849 (ott.).
5. Shaw, R.J., Paez, J.G., Curto, M., Yaktine, A., Pruitt, W.M., Saotome, I., O'Bryan, J.P., Gupta, V., Ratner, N., Der, C.J., Jacks, T., McClatchey, A.I., The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 1:1 (2001), 63–72 (lug.).
6. James, M.F., Han, S., Polizzano, C., Plotkin, S.R., Manning, B.D., Stemmer-Rachamimov, A.O., Gusella, J.F., Ramesh, V., NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell. Biol. 29:15 (2009), 4250–4261 (ago.).
7. Curto, M., Cole, B.K., Lallemand, D., Liu, C.-H., McClatchey, A.I., Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell Biol. 177:5 (2007), 893–903 (giu.).
8. Morrow, K.A., Shevde, L.A., Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim. Biophys. Acta 1826:2 (2012), 400–406 (dic.).
9. Rong, R., Surace, E.I., Haipek, C.A., Gutmann, D.H., Ye, K., Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 23:52 (2004), 8447–8454 (nov.).
10. Zhao, B., Li, L., Lei, Q., Guan, K.-L., The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24:9 (2010), 862–874 (mag.).
11. Yin, F., Yu, J., Zheng, Y., Chen, Q., Zhang, N., Pan, D., Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 154:6 (2013), 1342–1355 (set.).
12. Hamaratoglu, F., Willecke, M., Kango-Singh, M., Nolo, R., Hyun, E., Tao, C., Jafar-Nejad, H., Halder, G., The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 8:1 (2006), 27–36 (gen.).
13. Benhamouche, S., Curto, M., Saotome, I., Gladden, A.B., Liu, C.-H., Giovannini, M., McClatchey, A.I., Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 24:16 (2010), 1718–1730 (ago.).
14. Carruba, G., Aromatase in nontumoral and malignant human liver tissues and cells. Ann. N. Y. Acad. Sci. 1155 (2009), 187–193 (feb.).
15. Carruba, G., Miceli, V., Cocciadiferro, L., Zarcone, M., Agostara, B., Montalto, G., Granata, O.M., Estrogen signalling through amphiregulin may be implicated in human hepatocellular carcinoma. Horm. Mol. Biol. Clin. Investig. 5:3 (2011), 153–160 (mar.).
16. Miceli, V., Cocciadiferro, L., Fregapane, M., Zarcone, M., Montalto, G., Polito, L.M., Agostara, B., Granata, O.M., Carruba, G., Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. Omics J. Integr. Biol. 15:5 (2011), 313–317 (mag.).
17. Granata, O.M., Cocciadifero, L., Campisi, I., Miceli, V., Montalto, G., Polito, L.M., Agostara, B., Carruba, G., Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells. J. Steroid Biochem. Mol. Biol. 113:3–5 (2009), 290–295 (feb.).
18. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61:2 (2011), 69–90 (apr.).
19. Bosch, F.X., Ribes, J., Díaz, M., Cléries, R., Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:Suppl. 1 (2004), S5–S16 (nov.).
20. Shi, L., Feng, Y., Lin, H., Ma, R., Cai, X., Role of estrogen in hepatocellular carcinoma: is inflammation the key?. J. Transl. Med., 12, 2014, 93.
21. Laroche, G., Liver and sex hormones. Rev. Int. Hépatol. 3:5 (1953), 579–601.
22. Nagasue, N., Kohno, H., Hepatocellular carcinoma and sex hormones. HPB Surg. World J. Hepatic Pancreat. Biliary Surg. 6:1 (1992), 1–6.
23. Grimaldi, C., Bleiberg, H., Gay, F., Messner, M., Rougier, P., Kok, T.C., Cirera, L., Cervantes, A., De Greve, J., Paillot, B., Buset, M., Nitti, D., Sahmoud, T., Duez, N., Wils, J., Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J. Clin. Oncol. 16:2 (1998), 411–417 (feb.).
24. Di Maio, M., De Maio, E., Morabito, A., D'Aniello, R., De Feo, G., Gallo, C., Perrone, F., Hormonal treatment of human hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 1089 (2006), 252–261 (nov.).
25. Wang, Z., Zhang, X., Shen, P., Loggie, B.W., Chang, Y., Deuel, T.F., A variant of estrogen receptor-{alpha}, hER36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U. S. A. 103:24 (2006), 9063–9068 (giu.).
26. Su, X., Xu, X., Li, G., Lin, B., Cao, J., Teng, L., ER36: a novel biomarker and potential therapeutic target in breast cancer. OncoTargets Ther. 7 (2014), 1525–1533.
27. Shi, L., Dong, B., Li, Z., Lu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., Wang, Z., Xie, Y., Expression of ER36, a novel variant of estrogen receptor, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 27:21 (2009), 3423–3429 (lug.).
28. Wang, Q., Zhang, W., Yang, J., Liu, Y.-L., Yan, Z.-X., Guo, Z.-J., Li, Y.-J., Bian, X.-W., High ERα36 expression level and membrane location predict poor prognosis in renal cell carcinoma. Medicine (Baltimore), 048, 2015 (lug.).
29. Berasain, C., Castillo, J., Perugorría, M.J., Prieto, J., Avila, M.A., Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett. 254:1 (2007), 30–41 (ago.).
30. Berasain, C., Avila, M.A., Amphiregulin. Semin. Cell Dev. Biol. 28 (2014), 31–41 (apr.).
31. Britton, D.J., Hutcheson, I.R., Knowlden, J.M., Barrow, D., Giles, M., McClelland, R.A., Gee, J.M.W., Nicholson, R.I., Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat. 96:2 (2006), 131–146 (mar.).
32. Deng, H., Zhang, X.-T., Wang, M.-L., Zheng, H.-Y., Liu, L.-J., Wang, Z.-Y., ER36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. PLoS One, 8034, 2014.
33. LaMarca, H.L., Rosen, J.M., Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res. BCR, 9(4), 2007, 304.